Testicular Cancer Clinical Trial
Official title:
Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk
Testis cancer with germ cells is the most frequent cancer of young men and its incidence is
in constant increase in many industrialized countries, as in France. An increased risk of
developing testis cancer has been described in patients with testicular ectopia history and
testicular cancer history (controlateral testicular cancer) and more recently suggested in a
population of hypofertile men with altered spermatogenesis. To a better understanding of
this risk, an attempt of characterization of this group of patients has been proposed in the
present work.
The general objective of this project is to characterize morphological and molecular markers
of hypofertility which could serve as predictive markers of testis malignant transformation.
In this project conducted in 3 establishments, the investigators propose:
- To select a population of hypofertile patients exhibiting compatible clinical and
morphological characters with a high risk of testis tumoral transformation (secretory
azoospermia and/or a history of testicular ectopia. To determine the spermatogenic
arrests on histological criteria (score of Jonhsen).
- To study the expression of four proteins or family of proteins suspected of being
involved in testis tumorogenesis such as: the Placenta Alkaline Phosphatase (PLAPE),
cyclin A1, VASA and connexin (Cx) by immunohistochemistry and by real-time quantitative
RT-PCR analysis real-time analyses.
- To establish a possible correlation between the clinical data, spermatogenesis arrest
and the expression of these biomarkers.
These approaches would allow to identify, in this population of hypofertile patients,
subgroups of men who could develop tumours with germ cells, and subsequently to propose
potential biomarkers for testis cancer. A more clinical observation of these subgroups will
be also proposed.
Status | Terminated |
Enrollment | 44 |
Est. completion date | June 2011 |
Est. primary completion date | January 2009 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: - Patients with infertility azoospermia - Age 18 to 35 years - Definition of clinical and biological character of azoospermia: testicular volume less than 10 ml and FSH more than 10 IU / l - Normal karyotype - Surgical exploration included in a standardized medical aid to procreation - Testicular biopsy performed by traditional surgery - Patient informed about the research protocol and having signed consent to conduct a further testicular biopsy included in this study. Exclusion Criteria: - adults protected by law, minors - Individuals who are not affiliated to a social security - Subjects hospitalized for any reason other than research. - Patients will be used to support reproductive techniques: - Positive serology (HIV, hepatitis ...). - Patients with karyotype anomalies and unfavourable genetic counselling |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | CHU de Nice | Nice |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nice |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Analysis of 4 recognized tumorogenesis biomarkers in testicular biopsies of a population of hypofertiles men in theory supposed to present an increased incidence of testicular cancer development | 4 years | No | |
Secondary | Identification of spermatogenic achieving by conventional histology (analysis of Jonhsen's score) | 4 years | No | |
Secondary | Establishment of one or more correlation (s) between the level of expression of biomarkers of tumorogenesis: Jonhsen score, the rate of circulating spermatogenesis serum markers (AMH, inhibin ...). | 4 years | No | |
Secondary | Establishment of a correlation between the level of expression of of tumorogenesis testicular biomarkers, the presence of testicular microlithiasis and carcinoma in situ of the testis | 4 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00772694 -
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
|
Phase 2 | |
Completed |
NCT00705094 -
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
|
N/A | |
Terminated |
NCT00531687 -
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
|
Phase 2 | |
Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
Active, not recruiting |
NCT03142802 -
Low-Dose CT - Stage I Testicular Cancer
|
N/A | |
Recruiting |
NCT03232541 -
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
|
N/A | |
Completed |
NCT03557177 -
Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
|
||
Active, not recruiting |
NCT01783145 -
Shared Care Follow-up After Chemotherapy for Testicular Cancer
|
||
Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
Completed |
NCT02573584 -
Vascular Fingerprint Validation Study
|
||
Recruiting |
NCT05670938 -
Follow-up After Surgery for Testicular Cancer
|
||
Recruiting |
NCT02994758 -
Development of Diagnostics and Treatment of Urological Cancers
|
N/A | |
Completed |
NCT02991209 -
Study of Testosterone vs Placebo in Testicular Cancer Survivors
|
Phase 2/Phase 3 | |
Completed |
NCT02602041 -
Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
|
||
Completed |
NCT02092740 -
REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg
|
N/A | |
Completed |
NCT01482741 -
Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging
|
N/A | |
Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 | |
Completed |
NCT01242631 -
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
|
Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Completed |
NCT00183820 -
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
|
Phase 2 |